SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 54.74-2.1%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (9232)9/30/2003 9:04:46 PM
From: Miljenko Zuanic  Read Replies (2) of 52153
 
<<Axonyx said the compound, called Phensarine, could be given a quick review by regulators depending on results of late-stage testing now underway in Europe, but it still expects to launch a pivotal-stage U.S. trial of the drug.

To gain FT status, they will need to prove that Ph IS NOT me-too AC-inhibitor? Most likely they can't! Have no idea why they are *pumping*, but someone (broker looking for fast profit) must be behind their act, imo.

Miljenko
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News